PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 601–700 of 1,001
Cham, L. B., Dulgeroff, L. B. T., Tal, M. C., Adomati, T., Li, F., Bhat, H., Huang, A., Lang, P. A., Moreno, M. E., Rivera, J. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.058 · Cited by 48
Self-citationMola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 47
A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer
Liu, J., Zhang, S., Dai, W., Xie, C., & Li, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.586414 · Cited by 55
Copper Sulfide Nanoparticle‐Redirected Macrophages for Adoptive Transfer Therapy of Melanoma
Xu, J., Zheng, B., Zhang, S., Liao, X., Tong, Q., Wei, G., Yu, S., Chen, G., Wu, A., Gao, S., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008022 · Cited by 51
da Silva, R. B., Leitao, R. M., Pechuan-Jorge, X., Werneke, S. W., Oeh, J., Javinal, V., Wang, Y., Phung, W., Everett, C., Nonomiya, J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01153-x · Cited by 49
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment
Li, R., Huang, B. Q., Tian, H., & Sun, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1096717 · Cited by 57
Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages
Li, S., Guo, Y.-L., Tian, J.-W., Zhang, H., Li, R., Gong, P., & Yu, Z. (2023) · Cancers · doi:10.3390/cancers15102717 · Cited by 51
Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches
Yura, Y., & Hamada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311179 · Cited by 50
Macrophages: Targets for next-generation cancer immunotherapy
Sun, X., Park, M. D., Mérad, M., & Brown, B. D. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.020 · Cited by 56
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 51
Liao, Z., Fa, Y., Kempson, I. M., & Tseng, S. ‐. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00618 · Cited by 49
Karihtala, K., Leivonen, S., Brück, O. E., Karjalainen‐Lindsberg, M., Mustjoki, S. M., Pellinen, T. S., & Leppä, S. (2020) · Cancers · doi:10.3390/cancers12040877 · Cited by 47
Kim, Y. J., Won, C. H., Lee, M. W., Choi, J. H., Chang, S. E., & Lee, W. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082500 · Cited by 52
Xiang, W., Shi, R., Zhang, D., Kang, X., Zhang, L., Yuan, J., Zhang, X., & Miao, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00327-z · Cited by 47
Remodeling Macrophages by an Iron Nanotrap for Tumor Growth Suppression
Sang, Y., Deng, Q., Cao, F., Liu, Z., You, Y., Liu, H., Ren, J., & Qu, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c05392 · Cited by 47
Kim, M. J., & Ha, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767466 · Cited by 54
Keenan, B. P., McCarthy, E. E., Ilano, A., Yang, H., Zhang, L., Allaire, K. M., Fan, Z., Li, T. Y., Lee, D. S., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111384 · Cited by 49
Immune responses to human papillomavirus infection and vaccination
Kiamba, E. W., Goodier, M. R., & Clarke, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591297 · Cited by 57
Waele, J. D., Marcq, E., Audenaerde, J. R. M. V., Loenhout, J. V., Deben, C., Zwaenepoel, K., de Kelft, E. V., der Planken, D. V., Menovsky, T., den Bergh, J. M. J. V., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1407899 · Cited by 50
Generation of universal and hypoimmunogenic human pluripotent stem cells
Ye, Q., Sung, T., Yang, J., Ling, Q., He, Y., & Higuchi, A. (2020) · Cell Proliferation · doi:10.1111/cpr.12946 · Cited by 48
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 49
Du, R., Wang, C., Zhu, L., & Yang, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102236 · Cited by 45
Immune Dysregulation in Obesity
Jiang, Z., Tabuchi, C., Gayer, S. G., & Bapat, S. P. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-015350 · Cited by 52
Laengle, J., Kabiljo, J., Hunter, L., Homola, J., Prodinger, S., Egger, G., & Bergmann, M. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000195 · Cited by 47
Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 48
Davidov, V., Jensen, G. L., Mai, S., Chen, S., & Pan, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01842 · Cited by 47
The functions of autophagy at the tumour‐immune interface
Luo, X., Qiu, Y., Dinesh, P., Gong, W., Jiang, L., Feng, X., Li, J., Jiang, Y., Lei, Y. L., & Chen, Q. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16331 · Cited by 46
Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages
Dudzinski, S. O., Bader, J. E., Beckermann, K. E., Young, K. L., Hongo, R. A., Madden, M. Z., Abraham, A., Reinfeld, B. I., Ye, X., MacIver, N. J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001152 · Cited by 53
TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization
Han, Y., Sun, J., Yang, Y., Liu, Y., Lou, J., Pan, H., Yao, J., & Han, W. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73264 · Cited by 47
Hallett, R. M., Bonfill‐Teixidor, E., Iurlaro, R., Arias, A., Raman, S., Bayliss, P. E., Egorova, O., Neva-Alejo, A., McGray, A. R., Lau, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1888 · Cited by 45
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 46
Zhou, S.-N., Pan, W. T., Pan, M.-X., Luo, Q.-Y., Zhang, L., Lin, J., Zhao, Y.-J., Yan, X., Yuan, L.-P., Zhang, Y.-X., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06203-8 · Cited by 44
Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy
Zhao, Y., Mamuti, M., An, H., Fang, X., Zhao, Y., & Wang, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120552 · Cited by 47
Noninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 45
Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
Scheffel, T. B., Grave, N., Vargas, P., Diz, F. M., Rockenbach, L., & Morrone, F. B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.617385 · Cited by 50
Mi, Y., Han, J., Zhu, J., & Jin, T. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02495-7 · Cited by 48
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 45
Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
Boustani, J., Lecoester, B., Baude, J., Latour, C., Adotévi, O., Mirjolet, C., & Truc, G. (2021) · Cancers · doi:10.3390/cancers13194893 · Cited by 51
Izquierdo, E., Vorholt, D., Blakemore, S. J., Sackey, B., Nolte, J. L., Barbarino, V., Schmitz, J., Nickel, N., Bachurski, D., Lobastova, L., et al. (2022) · Blood · doi:10.1182/blood.2021014007 · Cited by 48
Gata6+ resident peritoneal macrophages promote the growth of liver metastasis
Hossain, M., Shim, R., Lee, W., Sharpe, A. H., & Kubes, P. (2022) · Nature Communications · doi:10.1038/s41467-022-32080-y · Cited by 47
Zhao, C.-C., Han, Q.-J., Ying, H.-Y., Gu, X.-X., Yang, N., Li, L.-Y., & Zhang, Q. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2032918 · Cited by 46
Brandi, N., & Renzulli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108598 · Cited by 45
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Lee, T.-A., Tsai, E.-Y., Liu, S.-H., Hung, S.-D. H., Chang, S., Chao, C.-H., Lai, Y., Yamaguchi, H., & Li, C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2664 · Cited by 48
The role of PKM2 in cancer progression and its structural and biological basis
Wu, B., Liang, Z., Lan, H., Teng, X., & Wang, C. (2024) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-024-01007-0 · Cited by 50
Molecular imaging to enlighten cancer immunotherapies and underlying involved processes
van der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.007 · Cited by 44
Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
Jiao, P., Geng, Q., Jin, P., Su, G., Teng, H., Dong, J., & Yan, B. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666181112114958 · Cited by 44
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
Zhou, X., Liu, Y., Hu, M., Wang, M., Liu, X., & Huang, L. (2021) · Science Advances · doi:10.1126/sciadv.abb6596 · Cited by 44
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1382 · Cited by 47
Jiang, L., Zhang, N., Chen, S., He, J., Liu, Y., Han, Y.-Q., Shi, X., Yang, J., Mu, D.-Y., Fu, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679928 · Cited by 42
Wei, T., Wang, K., Liu, S., Fang, Y., Hong, Z., Liu, Y., Zhang, H., Yang, C. J., Ouyang, G., & Wu, T. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112090 · Cited by 43
The regulatory network of the chemokine CCL5 in colorectal cancer
Zhang, X., Zhang, X., Wang, Y., Fang, Y., Li, M., Liu, X., Luo, H.-Y., & Tian, Y. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2205168 · Cited by 43
Biology and function of exosomes in tumor immunotherapy
Liu, C., Xia, C., & Xia, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115853 · Cited by 47
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E., et al. (2024) · Stem cell research & therapeutics · doi:10.1186/s13287-024-03810-4 · Cited by 40
mTOR at the Transmitting and Receiving Ends in Tumor Immunity
Guri, Y., Nordmann, T. M., & Roszik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00578 · Cited by 42
Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
Schürch, C. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00152 · Cited by 45
Perry, A., Graffeo, C. S., Carlstrom, L. P., Raghunathan, A., Driscoll, C. L. W., Neff, B. A., Carlson, M. L., Parney, I. F., Link, M. J., & Gompel, J. J. V. (2019) · Journal of neurosurgery · doi:10.3171/2019.7.jns19879 · Cited by 43
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 44
Lepland, A., Asciutto, E. K., Malfanti, A., Simón‐Gracia, L., Sidorenko, V., Vicent, M. J., Teesalu, T., & Scodeller, P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00226 · Cited by 42
Xu, J., Zhao, J., Wang, J., Sun, C., & Zhu, X. (2021) · Medicine · doi:10.1097/md.0000000000025318 · Cited by 44
Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis
Wang, Y., Zhao, C., Liu, Y., Wang, C., Jiang, H., Hu, Y., & Wu, J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00073 · Cited by 45
Polyaniline-Based Glyco-Condensation on Au Nanoparticles Enhances Immunotherapy in Lung Cancer
Su, W., Chang, L.-C., Song, W.-H., Yang, L., Wang, L., Chia, Z., Chin, Y., Shan, Y.-S., Huang, C., & Yeh, C. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03839 · Cited by 43
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 43
Wang, H., Zhao, C., Santa-Maria, C. A., Emens, L. A., & Popel, A. S. (2022) · iScience · doi:10.1016/j.isci.2022.104702 · Cited by 49
Ye, Z.-H., Yu, W., Huang, M., Chen, J., & Lu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.016 · Cited by 44
Zhou, B., Yang, Y., & Li, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195234 · Cited by 42
Liu, S., Huang, W., Yeh, H., Ko, C.-C., Shieh, H.-R., Hung, C., Chen, T.-Y., & Chen, Y.-J. (2019) · Cancers · doi:10.3390/cancers11040580 · Cited by 44
Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
Robust integration of multiple single-cell RNA sequencing datasets using a single reference space
Liu, Y., Wang, T., Zhou, B., & Zheng, D. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00859-x · Cited by 44
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
Jalili‐Nik, M., Soltani, A., Mashkani, B., Rafatpanah, H., & Hashemy, S. I. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107870 · Cited by 43
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Tian, L., Lei, A., Tan, T., Zhu, M., Zhang, L., Mou, H., & Zhang, J. (2021) · Kidney Diseases · doi:10.1159/000518664 · Cited by 42
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 46
Sui, X., Chen, C., Zhou, X., Wen, X., Shi, C., Chen, G., Liu, J., He, Z., Yao, Y., Li, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02612-5 · Cited by 45
Yao, Q., Ye, J., Chen, Y., Huang, L., Sun, L., He, Z., Wu, J., Zhao, Y., Zhao, X., Cai, A., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.148069 · Cited by 43
Sharma, N., Fan, X., Atolagbe, O. T., Ge, Z., Dao, K., Sharma, P., & Allison, J. P. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231263 · Cited by 43
Liu, X., Chen, Y., Liu, L., Hu, X., He, C., Zhou, Y., Ding, X., Luo, M., Yan, J., Liu, Q., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011235 · Cited by 45
Hou, B., Ye, J., Huang, L., Cheng, W., Chen, F., Zhou, H., Pan, J., Gao, J., Lai, Y., Zhao, Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq3940 · Cited by 43
Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance
Ocaña‐Guzmán, R., Vazquez-Bolaños, L. A., & Sada‐Ovalle, I. (2018) · Journal of Immunology Research · doi:10.1155/2018/8695157 · Cited by 42
Li, Y., Acharya, G., Elahy, M., Xin, H., & Khachigian, L. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.026 · Cited by 38
Meng, F., Su, Y., & Xu, B. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12804 · Cited by 44
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0905 · Cited by 54
Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy
Zhang, J., Jiang, M., Li, S., Zhang, Z., Sun, H., Yang, F., & Liang, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00050 · Cited by 40
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
Aubert, N., Brunel, S., Olive, D., & Marodon, G. (2021) · Cancers · doi:10.3390/cancers13123009 · Cited by 43
Tumor-associated macrophages in lymphoma: From mechanisms to therapy
Xiong, X., Xie, X., Wang, Z., Zhang, Y., & Wang, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109235 · Cited by 41
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39
Immune Editing: Overcoming Immune Barriers in Stem Cell Transplantation
Meissner, T. B., Schulze, H. S., & Dale, S. M. (2022) · Current Stem Cell Reports · doi:10.1007/s40778-022-00221-0 · Cited by 40
Myeloid effector cells in cancer
Schol, P. J., van Elsas, M. J., Middelburg, J., Twilhaar, M. K. N., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.002 · Cited by 41
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 40
Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike
Watanabe, E., Thampy, L. K., & Hotchkiss, R. S. (2018) · Acute Medicine & Surgery · doi:10.1002/ams2.363 · Cited by 41
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Li, Y., Liu, J., Gao, L., Liu, Y., Meng, F., Li, X., & Qin, F. X.-F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.006 · Cited by 44
Narayanapillai, S. C., Han, Y. H., Song, J. M., Kebede, M. E., Upadhyaya, P., & Kassie, F. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa059 · Cited by 43
Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance
Traba, J., Sack, M. N., Waldmann, T. A., & Antón, O. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657293 · Cited by 43
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
Awadasseid, A., Wu, Y., & Zhang, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119813 · Cited by 40
Hwang, W. C., Song, D., Lee, H., Oh, C., Lim, S. H., Bae, H. J., Kim, N. D., Han, G., & Min, D. S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00853-6 · Cited by 42
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Fitzgerald, K. N., Motzer, R. J., & Lee, C. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00666-2 · Cited by 42
Macrophage’s role in solid tumors: two edges of a sword
Jahandideh, A., Yarizadeh, M., Masjedi, M. N.-K., Fatehnejad, M., Jahandideh, R., Soheili, R., Eslami, Y., Zokaei, M., Ahmadvand, A., Ghalamkarpour, N., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02999-3 · Cited by 40
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 46
Kim, J. E., Lee, R. P., Yazigi, E., Atta, L., Feghali, J., Pant, A., Jain, A., Levitan, I., Kim, E. S., Patel, K. K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.007 · Cited by 40
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.